Marketing authorization

A marketing authorization (also written marketing authorisation) is a formal regulatory decision permitting a medicine to be placed on the market within a defined territory. It is issued by a national or supranational medicines agency after evaluating a sponsor's dossier covering the product's quality, safety, and clinical efficacy.

The decision is territorial. Each jurisdiction applies its own legal framework and evidentiary standards. The same compound can hold authorization in one territory, remain an investigational drug in a second, and carry no approved medical use in a third — simultaneously.

What it means in practice

To obtain authorization, a pharmaceutical sponsor submits a dossier across three domains: quality (manufacturing process, chemistry, purity controls), nonclinical safety (laboratory and animal-study data), and clinical evidence (human trial results, typically across Phases 1, 2, and 3). The agency's scientific committee evaluates the full submission and decides to approve, refuse, or request additional data.

Once granted, an authorization specifies the approved indications, dosage forms, route of administration, and prescribing conditions. Use outside those terms — known as off-label use — is governed separately in each jurisdiction and does not automatically void the underlying authorization.

Authorizations can be suspended or withdrawn if post-market surveillance surfaces hazards not apparent at the time of approval. Some are issued conditionally, with ongoing safety monitoring required as a formal term of the authorization itself.

How jurisdictions vary

The European Union uses the phrase marketing authorisation directly. The European Medicines Agency (EMA) operates a centralized procedure for certain medicine categories, issuing a single authorization valid across the EU and European Economic Area. Medicines outside that scope may be authorized through mutual recognition or decentralized national procedures.

The United States Food and Drug Administration does not use this term. The functional equivalent is a drug approval under a New Drug Application (for small-molecule medicines) or a Biologics License Application (for biological products). The FDA may attach structured safety programs — called Risk Evaluation and Mitigation Strategies — as conditions of approval.

The UK Medicines and Healthcare products Regulatory Agency, Health Canada, and Australia's Therapeutic Goods Administration each operate under independent statutory frameworks. An authorization from one body carries no standing in another's territory.

What is contested

In Australia, the Therapeutic Goods Administration authorized psilocybin and MDMA for use by approved prescribers in specified mental health indications before most other major regulators had acted on either compound. In the United States, an MDMA-assisted therapy program completed Phase 3 clinical trials and submitted for FDA approval; the agency's advisory committee voted against recommending approval, citing methodological concerns — particularly the difficulty of blinding participants and investigators — rather than a finding that the treatment was ineffective. The FDA subsequently declined the application.

These outcomes illustrate that an authorization decision reflects the submitted dossier, the agency's methodological standards, and its regulatory threshold — not a direct verdict on whether a compound produces clinical benefit.

Scope and currency

This entry describes marketing authorization as a regulatory concept. It is not legal or medical advice and does not state the law where the reader is located.

The position described here reflects circumstances as of 2026. Because regulatory status changes — authorizations are granted, refused, and withdrawn — the per-substance legal status section on each substance page carries its own jurisdiction, date, and source, and is the value to rely on.